YD54 | SMARCA2 degrader

MedKoo Cat#: 128832 | Name: YD54

Description:

WARNING: This product is for research use only, not for human or veterinary use.

YD54 is a potent SMARCA2 degrader. YD54 showed the antitumor growth inhibitory activity in SMARCA4 mutant xenografts. YD54 synergizes with the KRAS G12C inhibitor sotorasib to inhibit the growth of SMARCA4 and KRAS G12C comutant lung cancer cells.

Chemical Structure

YD54

CAS#N/A

Theoretical Analysis

MedKoo Cat#: 128832

Name: YD54

CAS#: N/A

Chemical Formula: C40H42FN9O6

Exact Mass: 763.3242

Molecular Weight: 763.83

Elemental Analysis: C, 62.90; H, 5.54; F, 2.49; N, 16.50; O, 12.57

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

YD54; YD 54; YD-54

IUPAC/Chemical Name

4-(2-(4-(4-((4-(3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl)piperazin-1-yl)methyl)-2-fluorophenyl)piperazin-1-yl)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione

InChi Key

WBWCGTJXNCHFJI-UHFFFAOYSA-N

InChi Code

InChI=1S/C40H42FN9O6/c41-28-22-25(24-47-14-18-49(19-15-47)32-23-29(44-45-37(32)42)26-4-1-2-6-33(26)51)8-9-30(28)48-16-12-46(13-17-48)20-21-56-34-7-3-5-27-36(34)40(55)50(39(27)54)31-10-11-35(52)43-38(31)53/h1-9,22-23,31,51H,10-21,24H2,(H2,42,45)(H,43,52,53)

SMILES Code

O=C1NC(C(N2C(C(C=CC=C3OCCN4CCN(C5=C(F)C=C(CN6CCN(C7=C(N)N=NC(C8=C(O)C=CC=C8)=C7)CC6)C=C5)CC4)=C3C2=O)=O)CC1)=O

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 763.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kotagiri S, Wang Y, Han Y, Liang X, Blazanin N, Nguyen PK, Jiang Y, Lissanu Y. Discovery of Novel, Potent and Orally Bioavailable SMARCA2 PROTACs with Synergistic Anti-tumor Activity in Combination with KRAS G12C Inhibitors. bioRxiv [Preprint]. 2024 Aug 26:2024.08.23.608456. doi: 10.1101/2024.08.23.608456. Update in: J Med Chem. 2025 Apr 25. doi: 10.1021/acs.jmedchem.4c02577. PMID: 39253520; PMCID: PMC11383272. 2: Kotagiri S, Wang Y, Han Y, Liang X, Blazanin N, Mazhar H, Sebastian M, Nguyen PK, Jiang Y, Lissanu Y. Discovery of Novel, Potent, and Orally Bioavailable SMARCA2 Proteolysis-Targeting Chimeras with Synergistic Antitumor Activity in Combination with Kirsten Rat Sarcoma Viral Oncogene Homologue G12C Inhibitors. J Med Chem. 2025 Apr 25. doi: 10.1021/acs.jmedchem.4c02577. Epub ahead of print. PMID: 40280558.